As the first self-expanding TPVR product approved in China and Europe, VenusP-Valve carries remarkable clinical value. Uniquely designed with both flared ends, the product ensures the blood flow of branchial artery with bare stents at the outflow end. It provides a stable multi-point anchoring system and enables easy delivery, with no need for pre-stenting before the procedure. Available in a variety of specifications with extensive applicability, VenusP-Valve is able to meet the needs of 85% of patients in the case of large RVOT.
"VenusP-Valve is able to eliminate pulmonary regurgitation in a wide range of anatomies," said Prof.
Clinical data reveals that VenusP-Valve demonstrates safety and efficacy on par with similar products, and excels in aspects such as rates of reintervention and arrhythmia. According to three-year follow-up data of the European clinical trial, the success rate for TPVR with VenusP-Valve is 100%. All-cause mortality and reintervention rates were zero. In addition, no moderate or severe pulmonary regurgitation was observed. Paravalvular leakage and tricuspid regurgitation were mild or below in 96.87% of subjects. The data suggest excellent performance, robust safety and reliability, and drastic and steady improvements in patients' cardiac function.
As the company's international flagship product, VenusP-Valve received CE marking under the Medical Devices Regulation (MDR) on April 8th, 2022, becoming the first Class III implantable cardiovascular device approved under the new MDR. In 2023, after receiving Investigational Device Exemption (IDE) approval from the
"Seeking effective treatments for major diseases that pose a serious threat to human health is what we do at
Following its first clinical implantation in 2013 by Academician Ge Junbo, Director of Cardiology at
About
For more information, please visit https://www.venusmedtech.com
Contacts:
Jill Liu
Public Relations Investor Relations
liujie@venusmedtech.com chenwenjuan@venusmedtech.com
Statements
*Provided for informational and academic purposes only, this content is not intended as professional medical or legal advice.
*
*VENUSMEDTECH, the stylized QI logo, VenusP-Valve, etc. are trademarks of
Copyright 2024. Venus Medtech(Hangzhou) Inc. All Rights Reserved.
View original content to download multimedia:https://www.prnewswire.com/news-releases/venus-medtech-venusp-valve-transcatheter-pulmonic-valve-replacement-system-granted-health-canada-approval-302052764.html
SOURCE
© Canada Newswire, source